» Articles » PMID: 29739895

Long-Term Survival Rates of Patients with Stage III-IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984-2013

Overview
Journal Oncologist
Specialty Oncology
Date 2018 May 10
PMID 29739895
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Long-term survival rates for patients with stage III-IV Hodgkin lymphoma, or advanced Hodgkin lymphoma (aHL), have increased substantially since the 1960s. Because large-scale research of aHL is rare, we aimed to demonstrate the differences in incidence and survival of aHL according to four patient variables in recent decades, with a focus on the outcomes of treatment of aHL and the advancement of public health care.

Materials And Methods: Data on aHL cases diagnosed during 1984-2013 were extracted from the Surveillance, Epidemiology, and End Results Program database. Relative survival, Kaplan-Meier, and Cox proportional hazards regression analyses were performed to identify prognosis indicators for aHL.

Results: The incidence rates for aHL were 1.1, 0.8, and 1.0 per 100,000 in the first, second, and third decades, respectively, during 1984-2013. The 120-month relative survival rate improved continuously in each decade from 58.5% to 64.6% to 72.1%. In addition, disparities in the 120-month relative survival rate between male and female patients and among patients of different races narrowed over time. The difference in long-term survival rate between the poor (medium and high poverty) and rich (low poverty) groups narrowed across the 3 decades.

Conclusion: The long-term survival rate for patients with aHL increased in each decade, whereas survival rate disparities according to sex, race, and socioeconomic status narrowed, except for older patients aged >60 years and the high-poverty group.

Implications For Practice: Long-term survival rates of patients with advanced Hodgkin lymphoma were elaborated in this article. The disparities according to sex, race, and socioeconomic status of survival condition were analyzed and showed the development of the public health care system and modern medicine technology.

Citing Articles

Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities.

Berkman A, Betts A, Beauchemin M, Parsons S, Freyer D, Roth M J Natl Cancer Inst. 2024; 116(9):1417-1428.

PMID: 38833671 PMC: 11378318. DOI: 10.1093/jnci/djae119.


Toward identification and intervention to address financial toxicity and unmet health-related social needs among adolescents and emerging adults with cancer and their caregivers: A cross-cultural perspective.

Beauchemin M, Solomon S, Michaels C, McHenry K, Turi E, Khurana R Cancer Med. 2024; 13(8):e7197.

PMID: 38659403 PMC: 11043682. DOI: 10.1002/cam4.7197.


Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study.

Sun P, Yang H, Wang Y, Zhao B, Nie M, Huang K Ann Hematol. 2023; 103(3):793-801.

PMID: 37953379 DOI: 10.1007/s00277-023-05541-7.


Sex differences in lymphoma incidence and mortality by subtype: A population-based study.

Radkiewicz C, Bruchfeld J, Weibull C, Jeppesen M, Frederiksen H, Lambe M Am J Hematol. 2022; 98(1):23-30.

PMID: 36178436 PMC: 10092431. DOI: 10.1002/ajh.26744.


Survival analysis of 8785 malignant lymphoma cases in the oral and nasal cavities in the USA: a cohort study.

Jiang F, Yan A BMJ Open. 2021; 11(12):e048876.

PMID: 34911709 PMC: 8679073. DOI: 10.1136/bmjopen-2021-048876.


References
1.
Koshy M, Fairchild A, Son C, Mahmood U . Improved survival time trends in Hodgkin's lymphoma. Cancer Med. 2016; 5(6):997-1003. PMC: 4924356. DOI: 10.1002/cam4.655. View

2.
Lulla P, Heslop H . Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):390-396. PMC: 6142511. DOI: 10.1182/asheducation-2016.1.390. View

3.
Crump C, Sundquist K, Sieh W, Winkleby M, Sundquist J . Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood. Am J Epidemiol. 2012; 176(12):1147-58. PMC: 3571233. DOI: 10.1093/aje/kws212. View

4.
Gottschalk S, Ng C, Perez M, Smith C, Sample C, Brenner M . An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001; 97(4):835-43. DOI: 10.1182/blood.v97.4.835. View

5.
Goedert J, Bower M . Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection. Curr Opin Oncol. 2012; 24(5):531-6. PMC: 3604881. DOI: 10.1097/CCO.0b013e3283560697. View